☆ 4.6 Article

Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma A Phase 3 Randomized Clinical Trial

JAMA ONCOLOGY (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Oncology

Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial

Thomas Yau et al.

Summary: First-line nivolumab treatment did not significantly improve overall survival compared with sorafenib in patients with advanced hepatocellular carcinoma, but clinical activity and a favorable safety profile were observed in some patients.

LANCET ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study

Lin Shen et al.

Summary: Tislelizumab significantly improves overall survival in patients with advanced or metastatic ESCC, and has a tolerable safety profile. Patients with TAP >= 10% also demonstrate significant survival benefit with tislelizumab compared to chemotherapy.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Review Oncology

Systemic Treatment of Advanced Unresectable Hepatocellular Carcinoma after First-Line Therapy: Expert Recommendations from Hong Kong, Singapore, and Taiwan

Thomas Yau et al.

Summary: This article summarizes the latest data and expert opinion on selecting systemic treatment following first-line therapy in patients with unresectable advanced or metastatic HCC.

LIVER CANCER (2022)

添加到收藏夹

Review Oncology

Immunotherapy for advanced hepatocellular carcinoma: From clinical trials to real-world data and future advances

Kathrine S. Rallis et al.

Summary: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths worldwide. Immunotherapy has shown promise in treating HCC, but real-world data on its use is lacking. More high-quality prospective studies are needed to support clinical decision-making and address challenges in real-world practice.

WORLD JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Meeting Abstract Oncology

Camrelizumab (C) plus rivoceranib (R) vs. sorafenib (S) as first-line therapy for unresectable hepatocellular carcinoma (uHCC): A randomized, phase III trial

S. Qin et al.

ANNALS OF ONCOLOGY (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Global burden of primary liver cancer in 2020 and predictions to 2040

Harriet Rumgay et al.

Summary: The burden of liver cancer varies across the world, and it is a major cause of death in many countries. The number of liver cancer cases and deaths is predicted to increase, with a significant rise expected by 2040.

JOURNAL OF HEPATOLOGY (2022)

添加到收藏夹

Meeting Abstract Oncology

RATIONALE 309: A randomized, global, double-blind, phase III trial of tislelizumab (TIS) vs placebo, plus gemcitabine plus cisplatin (GP), as first-line treatment for recurrent/metastatic nasopharyngeal cancer (RM-NPC)

Y. Yang et al.

ANNALS OF ONCOLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Hepatocellular carcinoma

Josep M. Llovet et al.

Summary: Liver cancer, particularly hepatocellular carcinoma (HCC), poses a significant global health challenge with rising incidence projected to exceed 1 million cases by 2025. Infection by hepatitis B and C viruses remains a major risk factor for HCC, while non-alcoholic steatohepatitis is emerging as a more common risk factor in Western countries. Advances in systemic therapies for HCC, including immunotherapies and targeted therapies, are expected to revolutionize the management of this disease.

NATURE REVIEWS DISEASE PRIMERS (2021)

添加到收藏夹

Letter Oncology

Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines

A. Vogel et al.

ANNALS OF ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer A Phase 3 Randomized Clinical Trial

Jie Wang et al.

Summary: This study showed that tislelizumab combined with chemotherapy can significantly improve progression-free survival in patients with advanced squamous non-small-cell lung cancer, providing potential benefits in clinical practice.

JAMA ONCOLOGY (2021)

添加到收藏夹

Meeting Abstract Oncology

Results from a global phase 2 study of tislelizumab, an investigational PD-1 antibody, in patients with unresectable hepatocellular carcinoma

M. Ducreux et al.

ANNALS OF ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study

Zhenggang Ren et al.

Summary: The study aimed to assess the efficacy of sintilimab plus IBI305 versus sorafenib as a first-line treatment for unresectable HBV-associated hepatocellular carcinoma in China, showing significant overall survival and progression-free survival benefits with acceptable safety profiles.

LANCET ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO

L-T Chen et al.

ANNALS OF ONCOLOGY (2020)

添加到收藏夹

Article Medicine, General & Internal

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Richard S. Finn et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Review Oncology

Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Status and Novel Perspectives

Piera Federico et al.

CANCERS (2020)

添加到收藏夹

Article Oncology

Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline

John D. Gordan et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Oncology

RATIONALE 301 study: tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma

Shukui Qin et al.

FUTURE ONCOLOGY (2019)

添加到收藏夹

Article Oncology

The binding of an anti-PD-1 antibody to FcγRI has a profound impact on its biological functions

Tong Zhang et al.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)

添加到收藏夹

Article Medicine, General & Internal

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

Masatoshi Kudo et al.

LANCET (2018)

添加到收藏夹

Article Oncology

Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

A. Vogel et al.

ANNALS OF ONCOLOGY (2018)

添加到收藏夹

Article Oncology

76PTislelizumab, an anti-PD-1 antibody, in patients with urothelial carcinoma (UC): Results from an ongoing phase I/II study

S Sandhu et al.

ANNALS OF ONCOLOGY (2018)

添加到收藏夹

Article Multidisciplinary Sciences

Prognosis of Unresectable Hepatocellular Carcinoma: Comparison of Seven Staging Systems (TNM, Okuda, BCLC, CLIP, CUPI, JIS, CIS) in a Chinese Cohort

Jin-feng Zhang et al.

PLOS ONE (2014)

添加到收藏夹

Editorial Material Medicine, General & Internal

被撤回的出版物: World Medical Association Declaration of Helsinki Ethical Principles for Medical Research Involving Human Subjects (Retracted article. See vol. 135, pg. 2149, 2021)

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)

添加到收藏夹

Article Medicine, General & Internal

Design and rationale for the non-interventional Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib (GIDEON) study

R. Lencioni et al.

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2010)

添加到收藏夹

Article Oncology

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. A. Eisenhauer et al.

EUROPEAN JOURNAL OF CANCER (2009)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.